# Eloralintide vs Petrelintide: Lilly vs Roche Amylin Agonists
> Note: PeptIQ is not a medical provider. Cross-trial comparisons are imperfect. Educational content only.
Eloralintide vs petrelintide is becoming the amylin-lane version of retatrutide vs tirzepatide — same broad pathway family, different sponsors and data packages.
One-Sentence Each
- Eloralintide (LY3841136): Lilly selective amylin receptor agonist with published Phase 2 dose map (1–9 mg weekly) and mean weight loss roughly 9–20% at 48 weeks; Phase 3 ENLIGHTEN underway.
- Petrelintide: Roche/Zealand long-acting amylin analog; ZUPREME-1 Phase 2 used five weekly dose arms with q4w escalation; public summaries cite up to ~10.7% mean loss at 42 weeks with a strong tolerability narrative.
Side-by-Side
| Eloralintide | Petrelintide | |
|---|---|---|
| Sponsor | Lilly | Roche / Zealand |
| Biology framing | Selective amylin agonist | Long-acting amylin analog |
| Cadence | Once weekly SC | Once weekly SC |
| Public dose clarity | High (1–9 mg Phase 2) | Lower until full mg tables publish |
| Standout efficacy headline | Up to ~20% @ 48 weeks (Phase 2) | Up to ~10.7% @ 42 weeks (Phase 2 topline/congress summaries) |
| Narrative emphasis | Efficacy ceiling + Phase 3 scale | Tolerability + gender-balanced learning trial |
| Combo interest | ± tirzepatide; macupatide cluster; ENLIGHTEN add-on to incretins | Planned work with CT-388; ZUPREME-2 in T2D |
Why the Percentages Are Not a Clean Ranking
Different:
- Trial durations (48 vs 42 weeks primary stories)
- Populations and lifestyle run-ins
- Estimands and dose-selection strategies
- How much of the dose-response curve is public
A 20% Phase 2 mean does not automatically "beat" a 10.7% Phase 2 mean for future labeled use — Phase 3 discontinuation rates and real-world persistence often reorder the leaderboard.
Shared Practical Lessons
Whether you follow Lilly or Roche amylin programs:
- Weekly injection habit design matters
- Titration speed drives GI tolerability
- Protein + lifting protect body composition
- Amylin is not a drop-in GLP-1, even when symptoms feel similar
- Gray-market names are not trial product
What Trackers Should Watch Next
- Eloralintide ENLIGHTEN obesity / T2D / incretin add-on readouts
- Full petrelintide ZUPREME-1 dose tables + body composition
- ZUPREME-2 (petrelintide in T2D population)
- Any head-to-head or network meta analyses once Phase 3 matures
FAQ
Q: Which is better — eloralintide or petrelintide?
A: Too early for a winner. Compare Phase 3 packages, access, and tolerability in the population that matches you.
Q: Are they the same as cagrilintide?
A: No. Three different amylin-pathway development stories (Lilly, Roche/Zealand, Novo).
Q: Can I switch between them?
A: Not a consumer decision today. These are investigational programs.
Bottom Line
Eloralintide vs petrelintide is Lilly's high Phase 2 efficacy map versus Roche/Zealand's weekly amylin analog with a tolerability-forward Phase 2 story. Pathway literacy first; leaderboard screenshots later.
Download PeptIQ to track whichever amylin or incretin protocol your clinician uses.
Educational content only. Not medical advice.
